|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Pistoia Alliance Publishes Free Guide to Accelerate the Implementation of FAIR Principles in Clinical Data |
 |
|
Co-authored by leading biopharma, biotech, and academic experts, the guide provides a first comprehensive overview on FAIR resources in the clinical space.
Boston, 25 January 2023, The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D today launched its freely accessible FAIR4Clin guide. The guide will help clinical regulators, biopharmaceutical and healthcare organizations to implement the FAIR principles (Findable, Accessible, Interoperable, Reusable) in clinical datasets. The diversity of data types, standards, and regulatory and privacy requirements, combined with the huge volume of clinical datasets, has presented a particular problem in life sciences R&D. The guide emphasizes the value of FAIR to the clinical space, including making data machine-readable to support AI, innovating in clinical trial design, and enabling the transfer of data between sponsors, CROs, and regulatory agencies. FAIR4Clin was co-authored by the Pistoia Alliance and leading experts in the field, including from AstraZeneca, Bayer, Roche, Genentech, Galapagos, The Hyve, Elixir, The University of Manchester and Oxford University.
“While the importance of FAIR data is well recognized in pre-clinical research and academia, implementation is not yet at a mature phase in the clinical domain. This guide will accelerate the adoption of FAIR principles and the move towards improved data standards in the clinical sector, ultimately creating a more collaborative research ecosystem that will bring new therapies to patients faster,” commented Giovanni Nisato, PhD, Project Lead at the Pistoia Alliance. “We’ve had huge interest in the FAIR project since its launch, even more so after the Covid-19 pandemic reiterated the importance of being able to reuse and share clinical trial and healthcare data to accelerate drug development timelines. We are now calling on even more organizations to get involved in the next phase of the project, which will examine the business value of FAIR and develop further tangible resources, enabling best practices across industries, increasing more interoperability and effective collaborations.”
The way clinical studies are conducted often leads to a fragmentation of datasets because of unharmonized metadata, which compounds existing issues with data variety and veracity. Silos emerge because clinical data is typically only generated for its primary purpose – often in an unFAIR format for regulators, rather than with interoperability and reuse in mind. For example, clinical studies must comply with the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) or Analysis Data Model (ADaM), but the focus of these standards is not on FAIR metadata elements. Consistent FAIR metadata at the study level could reduce fragmentation, for example by “tagging” terms from an appropriate ontology to enable access to synonyms and cross-references, resulting in semantically stronger metadata. This means data become interoperable and machine-readable, and are more easily integrated and interpreted including by external parties when value can be added.
"FAIRification at scale has become a main pillar in the R&D data strategy at Roche. The Pistoia Alliance is a strong partner to tackle foundational issues pre-competitively as an industry. In the second phase of the FAIR implementation project, we supported the FAIR4Clin Guide. The guide provides a comprehensive overview on FAIR resources in the clinical space to further support our FAIR journey," commented Martin Romacker, Senior Principal Scientist in Data and Analytics at Roche.
“The FAIR4Clin guide has been comprehensively developed by domain experts coordinating with multiple standards bodies and data integration alliances to provide a foundation for clinical data interoperability and reuse. We believe this to be the perfect starting point for improved clinical data stewardship that can galvanize these efforts in the research and medical community alike,” added Tom Plasterer PhD, Semantic Data Integration Lead, Oncology Data Science, AstraZeneca.
The guide is aimed at data practitioners in the clinical field, such as clinical data managers or analysts, as well as data practitioners in the research domain (registry data curators, terminology managers or bioinformaticians), and those in the post authorization domain (medical affair or market access). The first iteration of the guide focuses on implementing the FAIR principles related to data and its metadata for clinical trials and Real-World Evidence. This includes:
- Interventional data – clinical trial data from phases 1, 2 and 3 of clinical trials, which are conducted prior to product launch and phase 4 data collected after the product launch.
- Results summary data and the associated metadata such as the study description and protocol.
- Real-World Data, for example routinely collected healthcare data from hospitals and primary care sites, data from wearable sensors, or patient reported outcomes.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
mdgroup launches third fully compliant medical distribution centre in Europe
Bracknell, UK - 28 February 2023 – mdgroup, a leading global MedTech and patient health services company pioneering a patient-first approach to clinical research, has today opened its latest medical distribution centre in Amsterdam. One of three hubs worldwide, mdgroup’ s Horreum distribution centre - named after the Latin horrea or storage warehouses - provides sponsors across Europe with clinical trial supply procurement, storage, logistics, and delivery. Horreum integrates seamlessly with mdgroup’s range of specialist clinical services, including mobilehealth home health services and seacolehealth healthcare professional recruitment. This integrated approach to hybrid and decentralised clinical trials (DCT) conduct significantly reduces administrative burden on sites and sponsors, while protecting data quality, participant safety, and regulatory compliance.
More info >> |
|
 |
White Papers |
 |
|
Soothing the Logistical Headache of Clinical Trials
Equilibrium Travel Management
As many as 30 per cent of subjects on phase three clinical studies drop out. Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial. It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >> |
|
 |
Industry Events |
 |
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)
12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical
companies of manufacturing, primary and secondary packaging, purchasing,
and supply chain and procurement sectors, CMOs and CDMOs leaders, heads
from government and institution on 12-13, June, 2023 in Geneva,
Switzerland.
More info >> |
|
|
